Endocrine Abstracts

Background: Growth hormone (GH) deficiency causes visceral obesity and fatty liver and increases cardiovascular event risks. Because serum high-sensitivity C-reactive protein (hs-CRP) levels, which has been used to estimate those risks, was reported to be decreased by GH supplementation therapy in GH deficient patients, it has been suggested that inflammatory processes might be activated in GH deficient state. However, the clinical factors associated with increased hs-CRP leve...